

***AHSG* tagSNPs associate with type 2 diabetes and dyslipidemia: studies of metabolic traits in 7,683 Danish whites**

PhD Gitte Andersen¹, BSc Kristoffer Sølvsten Burgdorf¹, MSc Thomas Sparsø¹, DMSc Knut Borch-Johnsen^{1,2,3}, DMSc Torben Jørgensen², PhD Torben Hansen¹, DMSc Oluf Pedersen^{1,3}

¹Steno Diabetes Center, Gentofte, Denmark

²Research Centre for Prevention and Health, Glostrup University Hospital, Glostrup, Denmark

³Faculty of Health Science, University of Aarhus, Aarhus, Denmark

Running Title: *AHSG* variation and metabolism

Corresponding author:

Gitte Andersen, MSc, PhD
Steno Diabetes Center
Niels Steensens Vej 2, NSH2.16
DK-2820 Gentofte, Denmark
gtta@steno.dk

Received for publication 25 April 2007 and accepted in revised form 7 February 2008.

Additional information for this article can be found in an online appendix at
<http://diabetes.diabetesjournals.org>.

ABSTRACT

Objective: The gene encoding the $\alpha 2$ Heremans-Schmid glycoprotein, *AHSG*, is a credible biological and positional candidate gene for type 2 diabetes and the metabolic syndrome, and previous attempts to relate *AHSG* variation with type 2 diabetes and obesity in Swedish and French Caucasians have been largely successful. We related seven frequent *AHSG* tagSNPs to a range of metabolic traits including type 2 diabetes, obesity, and dyslipidemia.

Research Design And Methods: The polymorphisms were genotyped in 7,683 Danish whites using Taqman allelic discrimination or chip-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, providing a statistical power of more than 99% to replicate previous findings. Data were analysed in case-control and haplotype settings, and quantitative metabolic traits were examined for association. Moreover, epistatic effects between *AHSG* variants and *IRS1* and *ADRB2* polymorphisms were investigated.

Results: The -469T>G (rs2077119) and IVS6+98C>T (rs2518136) polymorphisms were associated with type 2 diabetes ($P=0.007$ and $P=0.006$, respectively, or $P_{\text{corr}}=0.04$ and $P_{\text{corr}}=0.03$ following correction for multiple hypothesis testing), and in a combined analysis of the present and a previous study -469T>G remained significant (OR 0.90 [0.84-0.97], $P=0.007$). Furthermore, two *AHSG* haplotypes were associated with dyslipidemia ($P=0.003$, $P_{\text{corr}}=0.009$). Thr248Met (rs4917) tended to associate with lower fasting and post-OGTT serum insulin release ($P=0.02$, $P_{\text{corr}}=0.1$ for fasting and $P=0.04$, $P_{\text{corr}}=0.2$ for area under the insulin curve) and improved insulin sensitivity estimated by the homeostasis model assessment of insulin resistance (9.0 mmol/l-pmol/l vs. 8.6 mmol/l-pmol/l, $P=0.01$, $P_{\text{corr}}=0.06$). Indications of epistatic effects of *AHSG* variants with the *IRS1* Gly971Arg polymorphism were observed for fasting serum triglyceride concentrations.

Conclusions: Based upon present and previous findings common variation in *AHSG* may contribute to the inter-individual variation in metabolic traits.

KEYWORDS. obesity, dyslipidemia, genetics, association, haplotype

ABBREVIATIONS. *AHSG*, $\alpha 2$ Heremans-Schmid glycoprotein; AUC, area under the curve; *IRS1*, insulin receptor substrate-1; LD, linkage disequilibrium; MAF, minor allele frequency; NGT, normal glucose tolerance; OGTT, oral glucose tolerance test; OR, odds ratio; SNP, single-nucleotide polymorphism; T2DM, type 2 diabetes mellitus;

The α_2 Heremans-Schmid glycoprotein (AHSG) is secreted mainly by the liver and is abundant in plasma. AHSG inhibits insulin-stimulated insulin receptor autophosphorylation, insulin-induced tyrosine phosphorylation of insulin receptor substrate-1 (IRS1), and the association of IRS1 with the p85 subunit of phosphatidylinositol-3 kinase *in vitro* (1-3). Elevated plasma AHSG was associated with insulin resistance in humans (4) and AHSG levels were higher in IGT subjects (5) and women with gestational diabetes (6). *Ahsg* knock-out mice demonstrate increased basal and insulin-stimulated insulin receptor phosphorylation, increased glucose clearance, and insulin sensitivity (7). Moreover, even on a high-fat diet and at old age *Ahsg* knock-out mice were resistant to weight gain and remained insulin-sensitive (7,8), while *Ahsg* expression was induced in the liver of Osborne-Mendel rats upon a high-fat diet (9). Human *AHSG* (chromosome 3q27) is a positional candidate gene for type 2 diabetes and the metabolic syndrome (10,11). Thus, attempts have been made to associate *AHSG* variation with metabolic phenotypes. Three polymorphisms (-843A>T/rs2248690, -469T>G/rs2077119, Thr248Met/rs4917) were associated with plasma cholesterol among 291 Swedish women for whom a relationship of -469T>G with insulin-mediated inhibition of lipolysis was also shown (12). Thr248Met and Thr256Ser (rs4918), which are in almost perfect linkage disequilibrium (LD), were examined among 176 Japanese subjects in relation to serum concentrations of AHSG which proved to be largely dependent on *AHSG* Thr248Met and Thr256Ser genotypes (13). Both of these single-nucleotide polymorphisms (SNPs) are in almost perfect LD with a third variant, IVS1-903A>G (rs2593813), which was associated with overweight/obesity among 504 Swedish men alone and in a haplotype combination with Thr248Met and Thr256Ser (14). In a

French study involving 1655 participants *AHSG* was re-sequenced and frequent SNPs (minor allele frequencies [MAF] >5%) were investigated for association with type 2 diabetes (15). Thr270Thr (rs1071592) was associated with type 2 diabetes with an odds ratio (OR) of 1.27 (95%CI 1.06-1.52, $P=0.008$) (15). Finally, Thr248Met was associated with increased sensitivity to the β_2 -adrenergic receptor in subcutaneous adipose tissue in 93 Swedish men, pointing to a possible role of *AHSG* variation in regulation of lipolysis (16). Here, we tagged the *AHSG* locus and added SNPs chosen from the current literature in order to examine the relationship of *AHSG* variation with different metabolic phenotypes (type 2 diabetes, obesity, dyslipidemia, and related quantitative traits) in Danish whites.

RESEARCH DESIGN AND METHODS

Patients. *AHSG* variants were genotyped in 7,683 Danish whites comprising 1) a population-based sample of middle-aged Danish whites sampled at Research Centre for Prevention and Health (17) ($n=6,256$), 2) a group of type 2 diabetic patients sampled through the out-patient clinic at Steno Diabetes Center ($n=1,069$), and 3) a population-based group of middle-aged glucose-tolerant subjects recruited from the Research Centre for Prevention and Health and Steno Diabetes Center ($n=358$). In study group 1 (3,067 men, 3,189 women) the age was 46 ± 8 years (mean \pm SD) and BMI $26.3\pm 4.6\text{kg/m}^2$. We made no observation of population stratification bias in this study sample (18). In the group of type 2 diabetic patients sampled at Steno Diabetes Center (653 men, 416 women) the age was 59 ± 11 years, age of clinical diagnosis 52 ± 11 years, BMI $29.5\pm 5.1\text{kg/m}^2$, and HbA_{1c} $8.1\pm 1.6\%$. In study group 3 (174 men, 184 women) the age was 62 ± 6 years and BMI $26.1\pm 3.7\text{kg/m}^2$. Study groups 1 and 3 underwent a standard 75 g oral glucose tolerance test (OGTT). All participants were stratified into subgroups for case-control studies of type 2 diabetes, obesity and

dyslipidemia with many participants being part of more than one group, and participants of study group 1 were analysed for association with quantitative metabolic traits. Informed written consent was obtained from all subjects before participation. The study was approved by the Ethical Committee of Copenhagen County and was in accordance with the principles of the Helsinki Declaration. Type 2 diabetes was defined according to WHO (19). Obesity was defined as described (20) and dyslipidemia was defined as fasting serum triglycerides ≥ 1.7 mmol/l or HDL-cholesterol < 0.9 mmol/l for men or < 1.0 mmol/l for women and/or current or previous treatment with lipid-lowering drugs (21).

Biochemical assays and anthropometrical measurements. Height, body weight, and waist and hip circumferences were measured as described (20). HbA_{1c}, plasma glucose, serum insulin, serum triglycerides and total and HDL-cholesterol were analyzed as described (18).

Genotyping. Eight *AHSB* variants were selected on the basis of previous positive findings and in order to tag the gene: -726G>T, -469T>G (rs2077119), IVS1-903A>G (rs2593813), Thr248Met (rs4917), IVS6+98C>T (rs2518136), Thr256Ser (rs4918), Thr270Thr (rs1071592), and 3'UTR+150C>T (rs11540663). Discordance between 938 random duplicate samples was $< 0.85\%$ and the genotyping success rate was $> 96\%$. For gene-gene interaction studies the *IRS1* Gly971Arg (rs1801278) and *ADRB2* Arg16Gly and Gln27Glu (rs1042713 and rs1042714) (22) polymorphisms were also analyzed. Genotyping of the variants was performed using Taqman allelic discrimination or chip-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. All genotype groups obeyed Hardy-Weinberg equilibrium in the population-based sample of Danes ($P > 0.2$).

Statistical analysis. Fisher's exact test was applied to examine differences in MAFs and genotype distributions between affected and unaffected subjects. Also, logistic regression

with adjustment for age, sex and BMI (where appropriate) was applied assuming an additive model. Power calculations were performed assuming ORs of 1.27 and 1.74 as observed in previous reports (14,15), a significance level of 95%, and a sample size of 1,005 which was the smallest number of subjects entering any analysis. A general linear model was used to test quantitative variables for differences between genotype groups among glucose-tolerant subjects not receiving any medication (glucose tolerance status determined according to (19)), and the *P* values describe an additive model. The degree of LD was estimated using the *genetics* package of RGui. The meta-analysis was performed using a fixed effects model and homogeneity was tested using Mantel-Haenszel. Haplotypes were inferred using the Carlson greedy algorithm on HapMap CEU data capturing all SNPs with MAF $> 5\%$ at $r^2 > 0.8$. Haplotype analysis was performed excluding all haplotypes with a frequency $< 5\%$ assuming an additive model. The two-way epistasis analysis was performed using general linear models: one with nine parameters (one for each genotype), where each SNP was assigned an additive and a dominance parameter, and one without interaction coefficients that consists of five parameters describing the epistasis (23). The epistatic effect was tested by comparing the two models (4 df) using ANOVA. The global null hypothesis was that all the parameters except the intercept are zero and the local null hypothesis was that one of the parameters is zero. All analyses were performed using SPSS version 14.0 and RGui version 2.4.1. A *P* value of less than 0.05 following correction for multiple testing using SNPSpD (24) was considered to be significant. The Nyholt method of correction was applied which takes into account the degree of LD between the SNPs and estimates the effective number of SNPs. An online interface is available at <http://genepi.qimr.edu.au/general/daleN/SNPSpD/>.

RESULTS

We genotyped eight *AHSB* SNPs (-726G>T, -469T>G, IVS1-903A>G, Thr248Met, IVS6+98C>T, Thr256Ser, Thr270Thr, and 3'UTR+150C>T) in a sample of 7,683 Danish whites. Estimates of pair-wise LD between the SNPs are shown in Supplementary Table A. High degrees of LD are due to some SNPs being chosen based on previous reports of association with metabolic traits. Due to the perfect LD between Thr248Met and Thr256Ser ($r^2=1$) we excluded Thr256Ser from further analyses. The seven remaining SNPs tagged *AHSB* (HapMap phase 2 release #21, MAF>5%, $r^2>0.8$).

Case-control studies of individual SNPs.

For each of the seven SNPs, four separate case-control studies were performed in which the genotype distributions and MAFs for type 2 diabetic patients were compared with those of glucose-tolerant subjects, obese subjects (BMI>30kg/m²) were compared with lean subjects (BMI<25kg/m²), dyslipidemic patients were compared with normolipidemic subjects, and finally we compared subjects with high waist circumference (>102cm for men and 88cm for women) with subjects having low waist circumference. None of the SNPs were associated with obesity (Supplementary Tables B and C) but the genotype distributions tended to differ between subjects with low and high waist circumference for IVS1-903A>G, Thr248Met and Thr270Thr (Supplementary Table C). We observed suggestive evidence for association between dyslipidemia and -469T>G ($P=0.02$, OR=0.91 (0.84-0.99) and IVS6+98C>T (Supplementary Table D), albeit not following correction for multiple hypothesis testing. Two SNPs (-469T>G, IVS6+98C>T) were significantly associated with type 2 diabetes (Table 1 and Supplementary Table E) where a difference in the MAF ($P=0.007$, $P=0.006$) as well as the genotype distributions ($P=0.03$, $P=0.02$) were observed, and the differences in MAFs persisted after correction (Table 1). These two SNPs along with Thr270Thr, which was

previously reported to associate with type 2 diabetes (15), were subjected to a combined case-control analysis with previous data (Figure 1). Only -469T>G remained significant ($P=0.007$) using a fixed effects model, although IVS6+98C>T approached significance ($P=0.05$). Attempting to replicate significant associations with obesity among Swedish men (14) we also tested a recessive model for the influence of the rare alleles of SNPs Thr248Met and IVS1-903A>G; however, we failed to replicate the previous finding ($P>0.05$).

Haplotype analyses. We performed haplotype analyses on type 2 diabetes, BMI-defined obesity, and waist circumference (excluding haplotypes with a frequency of less than 5%) without any positive findings ($P>0.05$). One haploblock was present with two specific haplotypes being significantly associated with dyslipidemia (Table 2, $P=0.002$ and $P=0.008$), indicating opposite functions of the minor alleles of -726G>T (haplotype #6, frequency 6%) and -469T>G (haplotype #1, frequency 40%). The global P -value was 0.003 before correction and 0.009 after correction.

Analyses of quantitative metabolic traits.

We investigated the relationships of the seven *AHSB* SNPs with quantitative metabolic traits and results for Thr248Met and IVS6+98C>T are shown in Table 3. Although some indications of a relationship with plasma glucose and serum insulin levels as well as homeostasis model assessment of insulin resistance (HOMA-IR) were observed, these were not statistically significant following correction for multiple testing. Likewise, an observed trend towards the minor -726T-allele being related to higher fasting serum cholesterol ($P=0.02$) did not remain significant ($P=0.1$).

Investigations of epistasis with *IRS1* and *ADRB2* polymorphisms. Due to a report of *Ahsg* knock-out mice showing increased insulin receptor phosphorylation in the insulin-stimulated state (7) and the evidence of *AHSB* inhibiting insulin-induced tyrosine phosphorylation of *IRS1* (2) we examined a possible two-way genetic interaction of

IRS1 Gly971Arg with the *AHSB* SNPs. Four *AHSB* SNPs (IVS1-903A>G, Thr248Met, Thr270Thr, IVS6+98C>T) showed some indications of epistatic effects with the functional *IRS1* Gly971Arg polymorphism on fasting serum triglyceride (uncorrected $P=1\cdot 10^{-5}$, $P=7\cdot 10^{-6}$, $P=0.0004$, $P=0.001$, respectively), where a relatively small group consisting of homozygous carriers of both minor alleles had increased triglyceride concentrations. No interaction was observed for fasting or postprandial serum insulin or plasma glucose ($P>0.05$). Additionally, as Thr248Met was suggested to increase adipose tissue sensitivity to the β_2 -adrenergic receptor (16) we investigated the interaction of the *AHSB* SNPs with two functional *ADRB2* polymorphisms (Arg16Gly, Gln27Glu). However, no indication of an interaction between SNPs in these two loci was observed for any of the examined traits ($P>0.05$).

DISCUSSION

The biological function of *AHSB* and the *Ahsg* knock-out mouse as well as the chromosomal localization of *AHSB* suggest a potential involvement of *AHSB* variation in the pathogenesis of metabolic diseases (2,7,10,11), and previous genetic epidemiological studies have shown association of *AHSB* variants with obesity (14), type 2 diabetes (15), and plasma cholesterol levels (12). In the present study we aimed at replicating these findings by genotyping the previously investigated variants as well as *AHSB* tagSNPs. Given the high MAF of the previously investigated *AHSB* variants our study has a statistical power of more than 99% to detect an association with type 2 diabetes with an OR of 1.27 (as observed among French whites (15)) or an association with obesity with an OR in the range 1.74 to 2.02 (as observed among Swedes (14)). In summary, we found a significant association of *AHSB* variants -469T>G and IVS6+98C>T with type 2 diabetes, a haplotype which is associated with dyslipidemia, and suggestions of epistasis

between *AHSB* and *IRS1* variants on fasting serum triglyceride concentrations.

We did not observe any association between Thr270Thr and type 2 diabetes as was found in the French population (15) and in a combined analysis of the French and the Danish data only the -469T>G variant remained significant. Despite of our relatively large-scale study this observation needs validation in future studies and such validation may be provided by genome-wide association studies. Intriguingly, four imputed *AHSB* SNPs from the publicly available WTCCC study were modestly associated with type 2 diabetes (25): -469T>G, IVS1-903A>G, Thr248Met, and Thr270Thr, P -values ranging from 0.002 to 0.08. Even though *AHSB* was not considered to be a first-priority gene in the WTCCC genome-wide association study these results add to the notion of *AHSB* playing a role in type 2 diabetes pathogenesis.

We made no observation of a relationship between *AHSB* variation and obesity as was suggested by previous reports; however, the present haplotype analyses and case-control studies indicate a role for -469T>G in dyslipidemia. This interpretation is supported by a previous study among Swedes where lower plasma cholesterol was observed in subjects homozygous for the minor allele (12). Moreover, there are strong indications that this variant is biologically functional as in a Japanese study serum *AHSB* levels were associated with -469T>G where the G-allele conferred the higher expression (26). Additionally, the results of the haplotype analysis together with the finding of higher fasting serum cholesterol suggest that the -726T-allele may act in the opposite direction to increase the risk of dyslipidemia, although this was not supported by the case-control study. The relatively low MAF (approximately 6%) and the resulting modest statistical power to detect subtle metabolic changes may account for this discrepancy. Also, the effect of *AHSB* SNPs on fasting serum triglyceride was completely masked in the absence of

IRS1 Gly971Arg as the increased levels of fasting serum triglyceride were only observed for carriers of both Gly971Arg and one of the *AHSG* SNPs. Ideally, statistical methods should be employed providing the necessary statistical power to detect what is expected to be small interactive effects in comparison with distinct main effects.

The Thr248Met variant is in perfect LD with Thr256Ser and as such represents a double non-synonymous amino acid substitution which has been shown to be functional in the sense that the two minor alleles result in lower *in vivo* serum levels of *AHSG* (13). The protein acts in phosphorylation of the insulin receptor tyrosine kinase (1) and has been associated with insulin resistance (4); thus, the observed nominal association in our study of Thr248Met with reduced fasting insulin and insulin resistance may provide a possible explanation of the mechanism by which *AHSG* variation modulates various metabolic phenotypes such as type 2 diabetes. In summary, we find that in the Danish population of middle-aged white people *AHSG* variation is related to several components of the metabolic syndrome. Due to the high degree of LD between some of the SNPs not all associations should be regarded as independent, and our findings

require future validation testing in large-scale settings. Also, future genotyping of as yet unidentified *AHSG* variants or other genetic variation in high LD with *AHSG* variants may assist to further explore this relationship.

ACKNOWLEDGMENTS

The study was supported by the Danish Medical Research Council, the Danish Diabetes Association, the Gerda and Aage Haensch Foundation, the A.P. Møller Foundation for the Advancement of Medical Science, and the Velux Foundation. This work is part of the project "Hepatic and adipose tissue and functions in the metabolic syndrome" (HEPADIP www.hepadip.org), which is supported by the European Commission as an integrated project under the 6th Framework Programme (LSHM-CT-2005-018734). The study received support from The FOOD Study Group/the Danish Ministry of Food, Agriculture and Fisheries and Ministry of Family and Consumer Affairs, grant no. 2101-05-0044. The authors wish to thank Annemette Forman, Inge-Lise Wantzin, Lene Aabo, and Marianne Stendal for technical assistance and Grete Lademann for secretarial support.

REFERENCES

1. Auberger P, Falquerho L, Contreres JO, Pages G, Le Cam G, Rossi B, Le Cam A. Characterization of a natural inhibitor of the insulin receptor tyrosine kinase : cDNA cloning, purification, and anti-mitogenic activity. *Cell* 58:631-640, 1989
2. Srinivas PR, Wagner AS, Reddy LV, Deutsch DD, Leon MA, Goustin AS, Grunberger G. Serum α_2 -HS-glycoprotein is an inhibitor of the human insulin receptor at the tyrosine kinase level. *Mol Endocrinol* 7:1445-1455, 1993
3. Mathews ST, Chellam N, Srinivas PR, Cintron VJ, Leon MA, Goustin AS, Grunberger G. α_2 -HSG, a specific inhibitor of insulin receptor autophosphorylation, interacts with the insulin receptor. *Mol Cell Endocrinol* 164:87-98, 2000
4. Mori K, Emoto M, Yokoyama H, Araki T, Teramura M, Koyama H, Shoji T, Inaba M, Nishizawa Y. Association of serum fetuin-A with insulin resistance in type 2 diabetic and nondiabetic subjects. *Diabetes Care* 29:468, 2006
5. Stefan N, Hennige AM, Staiger H, Machann J, Schick F, Kröber SM, Machicao F, Fritsche A, Häring HU. α_2 -Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. *Diabetes Care* 29:853-857, 2006
6. Kalabay L, Cseh K, Pajor A, Baranyi E, Csakany GM, Melczer Z, Speer G, Kovacs M, Siller G, Karadi I, Winkler G. Correlation of maternal serum fetuin/ α_2 -HS-glycoprotein concentration with maternal insulin resistance and anthropometric parameters of neonates in normal pregnancy and gestational diabetes. *Eur J Endocrinol* 147:243-248, 2002
7. Mathews ST, Singh GP, Ranalletta M, Cintron VJ, Qiang X, Goustin AS, Jen K-LC, Charron MJ, Jahnen-Dechent W, Grunberger G. Improved insulin sensitivity and resistance to weight gain in mice null for the Ahsg gene. *Diabetes* 51:2450-2458, 2002
8. Mathews ST, Rakhade S, Zhou X, Parker GC, Coscina DV, Grunberger G. Fetuin-null mice are protected against obesity and insulin resistance associated with aging. *Biochem Biophys Res Commun* 350:437-443, 2006
9. Lin X, Braymer HD, Bray GA, York DA. Differential expression of insulin receptor tyrosine kinase inhibitor (fetuin) gene in a model of diet-induced obesity. *Life Sci* 63:145-153, 1998
10. Kissebah AH, Sonnenberg GE, Myklebust J, Goldstein M, Broman K, James RG, Marks JA, Krakower GR, Jacob HJ, Weber J, Martin L, Blangero J, Comuzzie AG. Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. *Proc Natl Acad Sci USA* 97:14478-14483, 2000
11. Vionnet N, Hani EH, Dupont S, Gallina S, Francke S, Dotte S, De Matos F, Durand E, Lepretre F, Lecoeur C, Gallina P, Zekiri L, Dian C, Froguel P. Genomewide search for type 2 diabetes-susceptibility genes in French whites: evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2-diabetes locus on chromosome 1q21-q24. *Am J Hum Genet* 67:1470-1480, 2000.
12. Dahlman I, Eriksson P, Kaaman M, Jiao H, Lindgren CM, Kere J, Arner P. α_2 -Heremans-Schmid glycoprotein gene polymorphisms are associated with adipocyte insulin action. *Diabetologia* 47:1974-1979, 2004
13. Osawa M, Tian W, Horiuchi H, Kaneko M, Umetsu K. Association of α_2 -HS glycoprotein (AHSB, fetuin-A) polymorphism with AHSB and phosphate serum levels. *Hum Genet* 116:146-151, 2005
14. Lavebratt C, Wahlqvist S, Nordfors L, Hoffstedt J, Arner P. AHSB gene variant is associated with leanness among Swedish men. *Hum Genet* 117:54-60, 2005
15. Siddiq A, Lepretre F, Hercberg S, Froguel P, Gibson F. A synonymous coding polymorphism in the α_2 -Heremans-Schmid glycoprotein gene is associated with type 2 diabetes in French Caucasians. *Diabetes* 54:2477-2481, 2005

16. Lavebratt C, Dungen E, Hoffstedt J. Polymorphism of the AHSG gene is associated with increased adipocyte β 2-adrenoceptor function. *J Lipid Res* 46:2278-2281, 2005
17. Jørgensen T, Borch-Johnsen K, Thomsen TF, Ibsen H, Glümer C, Pisinger C. A randomized non-pharmacological intervention study for prevention of ischaemic heart disease: baseline results Inter99 (1). *Eur J Cardiovasc Prevention Rehab* 10:377-386, 2003
18. Andersen G, Overgaard J, Albrechtsen A, Glümer C, Borch-Johnsen K, Jørgensen T, Hansen T, Pedersen O. Studies of the association of the *GNB3* 825C>T polymorphism with components of the metabolic syndrome in whites. *Diabetologia* 49:75-82, 2006
19. Alberti KGMM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. *Diabet Med* 15:539-553, 1998
20. Gjesing AP, Andersen G, Albrechtsen A, Glümer C, Borch-Johnsen K, Jørgensen T, Hansen T, Pedersen O. Studies of associations between the Arg389Gly polymorphisms of the β ₁-adrenergic receptor gene (*ADRB1*) and hypertension and obesity in 7677 Danish white subjects. *Diabet Med* 24:392-397, 2007.
21. Sparsø T, Hussain MS, Andersen G, Hainerova I, Borch-Johnsen K, Jørgensen T, Hansen T, Pedersen O. Relationships between the functional PPAR α Leu162Val polymorphism and obesity, type 2 diabetes, dyslipidaemia, and related quantitative traits in studies of 5799 middle-aged white people. *Mol Genet Metab* 90:205-209, 2007.
22. Gjesing AP, Andersen G, Burgdorf KS, Borch-Johnsen K, Jørgensen T, Hansen T, Pedersen O. Studies of the associations between functional β ₂-adrenergic receptor variants and obesity, hypertension and type 2 diabetes in 7,808 white subjects. *Diabetologia* 50: 563-568, 2007
23. Cordell HJ. Epistasis: what it means, what it doesn't mean, and statistical methods to detect it in humans. *Hum Mol Genet* 11:2463-2468, 2002
24. Nyholt DR. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. *Am J Hum Genet* 74:765-769, 2004
25. The Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature* 447:661-678, 2007
26. Inoue M, Takata H, Ikeda Y, Suehiro T, Inada S, Osaki F, Arii K, Kumon Y, Hashimoto K. A promoter polymorphism of the α 2-HS glycoprotein gene is associated with its transcriptional activity. *Diab Res Clin Pract* 79:164-170, 2008

TABLE 1. Genotype distribution and minor allele frequencies of the *AHSG* -469T>G and IVS6+98C>T polymorphisms for the participants stratified according to glucose tolerance status

	NGT	T2DM	P_{GD} (P_{GDcorr})	P_{MAF} ($P_{MAFcorr}$)
-469T>G	$n=4,750$	$n=1,360$		
TT	1,392 (29)	441 (32)		
TG	2,315 (49)	657 (48)	0.03 (0.2)	
GG	1,043 (22)	262 (19)		
MAF (95%CI)	46.3 (45.3-47.3)	43.4 (41.6-45.3)		0.007 (0.04)
IVS6+98C>T	$n=4,712$	$n=1,336$		
CC	1,326 (28)	335 (25)		
CT	2,319 (49)	658 (49)	0.02 (0.1)	
TT	1,067 (23)	343 (26)		
MAF (95%CI)	47.3 (46.2-48.3)	50.3 (48.4-52.2)		0.006 (0.03)

Data are number of subjects with each genotype (% of each group) and frequencies of the minor allele (MAF) in percentages. All *P*-values were calculated using Fisher's exact test and compare genotype distributions and MAFs either nominally (P_{GD} and P_{MAF}) or corrected for multiple hypothesis testing (P_{GDcorr} and $P_{MAFcorr}$). Also, logistic regression was applied with adjustment for age, sex and BMI; however, this did not change the results. All genotype groups obeyed Hardy-Weinberg equilibrium.

TABLE 2. Analysis of common AHSG haplotypes in relation to dyslipidemia

#	-726G>T	-469T>G	IVS1-903A>G	Thr248Met	IVS6+98C>T	Thr270Thr	3'UTR+150C>T	Frequency (%)	Score	<i>P</i> (<i>P</i> _{corr})
1	G	G	T	C	C	C	C	40	-3.2	0.002 (0.006)
2	G	T	C	T	T	A	C	30	-0.8	0.4
3	G	T	T	C	T	C	T	6	1.1	0.3
4	G	T	C	T	T	C	C	8	1.4	0.2
5	G	T	T	C	T	C	C	6	1.8	0.08
6	T	T	T	C	C	C	C	6	2.6	0.008 (0.02)

Haplotypes with a frequency > 5% are shown. The global score *P*-value was 0.003 without correction for multiple hypothesis testing and 0.009 with correction.

TABLE 3. Anthropometric and metabolic characteristics of middle-aged glucose-tolerant Danish white subjects stratified according to AHSG Thr248Met and IVS6+98C>T genotype

	Thr248Met, <i>n</i> = 4,455			<i>P</i> (<i>P</i> <i>corr</i>)	IVS6+98C>T, <i>n</i> = 4,358			<i>P</i> (<i>P</i> <i>corr</i>)
	CC	CT	TT		CC	CT	TT	
<i>n</i> (men/women)	1,865 (893/972)	2,033 (913/1,120)	557 (266/291)		1,226 (580/646)	2,145 (980/1,165)	987 (456/531)	
Age (years)	45 ± 8	45 ± 8	46 ± 8		45 ± 8	45 ± 8	46 ± 8	
BMI (kg/m ²)	25.4 ± 3.9	25.6 ± 4.3	25.3 ± 3.9	0.7	25.5 ± 4.0	25.5 ± 4.2	25.5 ± 4.1	0.7
Waist-to-hip ratio	0.84 ± 0.08	0.84 ± 0.08	0.85 ± 0.08	0.8	0.84 ± 0.08	0.84 ± 0.08	0.84 ± 0.08	0.5
Plasma glucose (mmol/l)								
Fasting	5.3 ± 0.4	5.3 ± 0.4	5.3 ± 0.4	0.4	5.3 ± 0.4	5.3 ± 0.4	5.3 ± 0.4	0.4
30-min	8.2 ± 1.6	8.2 ± 1.5	8.1 ± 1.5	0.2	8.3 ± 1.6	8.2 ± 1.5	8.1 ± 1.5	0.03 (0.2)
120-min	5.5 ± 1.1	5.5 ± 1.1	5.4 ± 1.1	0.5	5.5 ± 1.1	5.5 ± 1.1	5.5 ± 1.1	0.5
AUC	182 ± 103	182 ± 100	175 ± 95	0.05	185 ± 102	181 ± 101	177 ± 98	0.04 (0.2)
Serum insulin (pmol/l)								
Fasting	38 ± 23	38 ± 23	36 ± 25	0.02 (0.1)	38 ± 23	38 ± 23	37 ± 24	0.2
30-min	287 ± 183	292 ± 175	271 ± 157	0.09	286 ± 183	294 ± 183	276 ± 156	0.1
120-min	168 ± 129	172 ± 135	158 ± 122	0.4	167 ± 128	173 ± 139	162 ± 119	0.7
AUC	21068 ± 13639	21398 ± 13293	19662 ± 11814	0.04 (0.2)	20986 ± 13602	21631 ± 13855	20078 ± 11659	0.09
Insulin resistance (mmol/l-pmol/l)								
HOMA-IR	9.0 ± 5.6	9.0 ± 5.7	8.6 ± 5.9	0.01 (0.06)	8.9 ± 5.6	9.0 ± 5.7	8.7 ± 5.7	0.2
Fasting serum lipids (mmol/l)								
Triglyceride	1.2 ± 0.8	1.2 ± 1.1	1.2 ± 0.9	0.8	1.2 ± 0.8	1.2 ± 1.1	1.2 ± 0.8	0.6
Total cholesterol	5.4 ± 1.0	5.4 ± 1.0	5.4 ± 1.1	0.5	5.5 ± 1.0	5.4 ± 1.0	5.5 ± 1.1	0.6
HDL-cholesterol	1.5 ± 0.4	1.5 ± 0.4	1.4 ± 0.4	0.3	1.5 ± 0.4	1.5 ± 0.4	1.5 ± 0.4	0.2

Data are means ± standard deviation. Values of serum insulin, values derived from insulin variables, and values of serum triglyceride were logarithmically transformed before statistical analysis. All analyses were made using an additive model. Calculated *P*-values were adjusted for age, sex, and BMI: genotype and sex were considered as fixed factors and age and BMI as covariates. Statistically significant *P* values were corrected for multiple hypothesis testing (*P**corr*). HOMA-IR was calculated as fasting plasma glucose (mmol/l) multiplied by fasting serum insulin (pmol/l) and divided by 22.5. AUC, area under the curve.




Figure 1.

Combined analyses of data from the present and a previous study (15) of *AHSG* polymorphisms in relation to type 2 diabetes. Data are estimated risks (95%CI) of type 2 diabetes when comparing the numbers of minor alleles of the *AHSG* Thr270Thr, IVS6+98C>T and -469T>G polymorphisms assuming a general model. Homogeneity between studies was tested (Mantel-Haenszel) but was observed only for -469T>G ($P=0.5$) and not for Thr270Thr ($P=0.006$) or IVS6+98C>T ($P=0.03$).